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Genetic Changes during Mouse Skin
umorigenesis
by Philip A. Burns,* Rod Bremner,* and Allan Balmain*
This paper describes specific genetic changes involving chromosome 7 in mouse skin tumors, the most
important consequence of which appears to be an alteration in the allelic balance of normal and mutant
H-ras genes. The use of restriction-fragment-length polymorphisms in F1 hybrid mice demonstrates that
trisomy of chromosome 7 is an early event preceding papilloma formation, and further events, such as
mitotic recombination, seem to occurduring progression to malignant carcinomas. There is some evidence
of a tumor-suppressor locus situated on chromosome 7.
H-ras Mutations in the Mouse Skin
System
The mouse skin tumorigenesis system provides a use-
ful animal model for multistage carcinogenesis. Initial
treatment ofthe dorsal skinwith asubcarcinogenic dose
of a carcinogen, such as dimethylbenzanthracene
(DMBA), induces a population of initiated cells. Sub-
sequent treatment with a noncarcinogenic tumor-pro-
moting agent, such as 12-0-tetradecanoyl-phorbol-13-
acetate (TPA), produces benign papillomas within 3
months. A proportion of these lesions spontaneously
progress to give malignant carcinomas. This system
therefore possesses at least three well-defined stages:
initiation, promotion, and progression.
Mutations of the proto-oncogene H-ras have been
found in both papillomas and carcinomas. The type of
mutations found correspond closely with the known mu-
tational specificity of the carcinogens used to initiate
the skin tumors (1). Thus, N-methyl-N'-nitro-N-nitro-
soguanidine (MNNG)-induced tumors have G:C to A:T
transition mutations, correlating with the mispairing
properties ofthe major premutagenic lesion of MNNG,
06-methylguanine. Likewise, DMBA induces a high
proportion of adenine adducts (2) and gives rise to tu-
mors with A:T transversions. Since the mice receive
only a single initiating dose of carcinogen, it would ap-
pear that mutations in H-ras represent one kind of in-
itiating event in mouse skin tumorigenesis. This con-
clusion is supported by the observation that Harvey
murine sarcoma virus (HaMSV), which carries a mu-
tationally activated H-ras gene, can substitute for the
initiating carcinogen treatment in this system (3).
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However, not all mouse skin tumors carry mutation-
ally activated H-ras genes, or, it would appear, any
alternative dominantly acting transforming genes.
Otherpathways oftumorinitiation must therefore exist
in this system.
H-ras Allele Imbalance in Mouse
Skin Tumors
The A:T to T:A transversion commonly found in
DMBA-induced tumors introduces a novel Xba I site
into the H-ras gene. Thus, on Southern transfers, it is
possible to distinguish bands corresponding to mutant
alleles from bands corresponding to normal alleles (4).
By comparing the densities of the relative bands, it is
observed that an allelic imbalance in favor of mutant
alleles is common in carcinomas (4). This has recently
also been shown to be the case forpapillomas (P. Burns,
R. Bremner, and A. Balmain, manuscript in prepara-
tion). The imbalance appears to represent some form of
duplication of the mutant allele. In addition, a propor-
tion of carcinomas also display homozygosity for the
mutant allele.
Thus, it would appear that in addition to activating
H-ras mutations, some form of gross chromosomal al-
teration of chromosome 7 is also a consistent, early
event in mouse skin tumorigenesis.
Use of F. Hybrids to Characterize
Chromosome 7 Abnormalities
It is difficult to study the nature ofallelic imbalances
or the loss of heterozygosity in inbred strains of labo-
ratory mice because of the general lack of useful re-
striction-fragment-length polymorphisms (RFLPs).
However, by generating F1 hybrids between strains of
mice carrying useful allele-specific markers on chro-BURNS ET AL.
mosome 7 and using these animals for generating skin
tumors, it has been possible to analyze the nature of
the genetic events involved in the generation of allelic
imbalance and homozygosity (Fig. 1). By looking at the
behavior of RFLPs at loci proximal (fes and Hbb) and
distal (int-2) to H-ras on chromosome 7, it has been
possible to show that nondisjunction events, leading to
trisomy, and mitotic recombination, leading to loss of
heterozygosity, are mainly responsible for generating
H-ras allelic imbalances (5). Trisomy of chromosome 7
in papillomas has also been observed using cytogenetic
analysis of DMBA-induced papillomas (6).
It is interesting to note, however, that those tumors
that do not have mutationally activated H-ras genes,
e.g., the majority of MNNG-induced tumors, do not
display abnormalities of chromosome 7 (Table 1).
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FIGURE 1. Use of F1 hybrids to characterize chromosomal altera-
tions.
Is Normal H-ras a Tumor-
Suppressor Gene?
The observations concerning the generation of hom-
ozygosity or allelic imbalance on chromosome 7 have at
leastthree possible explanations: a)the presence ofnor-
mal H-ras alleles may suppress the effect of mutant
alleles such that there may be a selective advantage,
with respect to tumorigenicity, in losing a normal allele
or duplicating a mutant allele; b) a simple increase in
the numberofmutantalleles, and concomittant increase
in the expression of mutant p21 protein, may confer a
selective growth advantage; and c) the loss of H-ras
alleles maybecoincidental withthe lossoflinked tumor-
suppressor genes (the observed trisomy ofchromosome
7 may represent the loss of a chromosome from a te-
traploid cell).
Suppression bynormal ras alleles could occurthrough
competition with mutant alleles for either transcription
factors at the DNA level or for effector molecules at
the protein level. There is much conflicting evidence
concerning this possibility. A recently discovered tu-
mor-suppressor gene, K-rev (7), has strong sequence
homology to ras and is able to induce reversion oftrans-
formed cells expressing mutant K-ras, perhaps through
competition for cellular factors. Loss orunderrepresen-
tation ofnormal ras alleles has been observed in a wide
variety of tumors (8-10), although this may simply be
the consequence ofchromosomal changes that increase
the copy number of mutant ras alleles. Marshall and
colleagues (11) have reintroduced normal N-Ras p21
protein into HT 1080 cells carrying mutant N-ras genes
and failed to observe reversion. However, the parental
HT1080 cells already express high levels of normal N-
Ras p21 and may have adopted an alternative route to
escape tumor suppression. Other studies have demon-
strated the ability of normal ras genes to act in an on-
cogenic (12) or anti-oncogenic fashion (13).
It is unlikely that the level of expression of mutant
ras is the sole or main determinant of tumorigenicity.
Sometumorigenic celllines expresslowlevelsofmutant
ras together with high levels of normal ras, whereas
othercelllines expresshighlevelsofmutant raswithout
becomingtumorigenic (11; Quintanillaet al., manuscript
in preparation).
Table 1. Correlation between H-ras mutations and chromosome 7 changes.
Induction protocola Number of H-ras mutation/
carcinomas chromosome 7 changes
Initiation Promotion analyzed +/+ +/- -/- -/+
DMBA TPA 19 19 0 0 0
DMBA DMBAITPA 1 1 0 0 0
MNNG TPA 4 2 0 2 0
MNNG MNNG 5 0 2 3 0
DMBA DMBA 8 4 0 4 0
aDMBA, dimethylbenzanthracene; TPA, 12-0-tetradecanoyl-phorbol-13-acetate; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine.
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A Tumor Suppressor on
Chromosome 7
A good reason for looking for chromosomal changes
involving mouse chromosome 7 is that regions of this
chromosome are syntenic with regions on the short arm
ofhuman chromosome 11 (14). These regions appear to
contain a number of potential tumor-suppressor loci,
including the Wilm's tumor locus and a gene that pre-
disposes for Wiedemann-Beckwith syndrome (14). In
addition, loss of alleles around lipl5 is a common fea-
ture of a variety of human tumor types (15-17). Loss
of heterozygosity at loci distal to Hbb on chromosome
7 was seen in four tumors in these studies. The H-ras
locus was involved in three of these cases, and the al-
terations may therefore have served primarily to in-
crease the copy number of mutant H-ras. However, in
one case, the loss of heterozygosity only involved a
marker distal to H-ras, supporting the proposal that a
tumor-suppressor gene may be located on chromosome
7 in the mouse.
Conclusions
In the mouse skin tumorigenesis system, gross al-
terations of chromosome 7 leading to trisomy and loss
of heterozygosity are a consistent feature of those tu-
mors carryingmutationallyactivated H-ras alleles (Fig.
2). The observation that most benign papillomas car-
rying mutant H-ras genes are trisomic for chromosome
7 suggests that nondisjunction leading to trisomy is a
relatively early event occurring during promotion. The
tumor-promoting agent that is used in this laboratory,
TPA, has been shown to induce aneuploidy in mouse
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FIGURE 2. Chromosome 7 changes occurring during mouse skin tu-
morigenesis.
epidermal cell lines (18) and may therefore be respon-
sible for these changes in vivo. The nature of the se-
lective advantage that these gross chromosomal
changes confer on tumor cells is not known, nor is it
known whether anincreased copy number ofmutant H-
ras or a relative decrease in the copy number ofnormal
H-ras is responsible. In addition to changes involving
the gene dosage of H-ras allele, there is also some evi-
dence from loss of heterozygosity studies for the pres-
ence of a tumor-suppressor locus distal to H-ras.
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